Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Myeloma

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations

Leukemia volume 19, pages 1466–1470 (2005)Cite this article

Abstract

Multiple myeloma (MM) is characterized by accumulation of clonal plasma cells (PCs). CD45, a key regulator of antigen-mediated signaling and activation in lymphocytes, is present in early stages of PCs development. We studied CD45 expression on MM PCs by flow cytometry, correlating it to important biological disease characteristics. Additionally, we examined the expression of various adhesion molecules on PCs. A total of 75 patients with untreated MM (29), relapsed MM (17), smoldering MM (12), and monoclonal gammopathy of undetermined significance (MGUS) (17) were studied. The proportion of PCs expressing CD45 was higher among those with early disease (MGUS or smoldering MM) compared to those with advanced disease (new or relapsed MM) (43 vs 22%; P=0.005). Among those with advanced disease, patients with bone lesions had a lower percentage of CD45-positive (CD45+) PCs; 14 vs 34% (P=0.02). Patients with high-grade angiogenesis had a lower percentage of CD45+ PCs; 13 vs 31% (P=0.03). The median overall survival for the CD45+ group (>20% PCs positive) was 39 vs 18 months for the CD45-negative (CD45−) group (P=0.07). The expression of CD138, CD56 and CD54 were higher among the CD45− PCs. This study demonstrates important biological correlates of CD45 expression on myeloma cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Thomas ML . The leukocyte common antigen family. Annu Rev Immunol 1989; 7: 339–369.

    Article  CAS  Google Scholar 

  2. Trowbridge IS, Thomas ML . CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994; 12: 85–116.

    Article  CAS  Google Scholar 

  3. Pellat-Deceunynck C, Bataille R . Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2004; 32: 293–301.

    Article  CAS  Google Scholar 

  4. Schneider U, van Lessen A, Huhn D, Serke S . Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol 1997; 97: 56–64.

    Article  CAS  Google Scholar 

  5. Mahmoud MS, Ishikawa H, Fujii R, Kawano MM . Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood 1998; 92: 3887–3897.

    CAS  PubMed  Google Scholar 

  6. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Otsuyama K et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 2003; 44: 1477–1481.

    Article  CAS  Google Scholar 

  7. Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Taniguchi O et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002; 99: 2172–2178.

    Article  CAS  Google Scholar 

  8. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K . Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003; 101: 3136–3141.

    Article  CAS  Google Scholar 

  9. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547–551.

    PubMed  Google Scholar 

  10. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332–2336.

    Article  CAS  Google Scholar 

  11. Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE . Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003; 102: 1075–1077.

    Article  CAS  Google Scholar 

  12. Witzig TE, Gonchoroff NJ, Katzmann JA, Therneau TM, Kyle RA, Greipp PR . Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol 1988; 6: 1041–1046.

    Article  CAS  Google Scholar 

  13. Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62: 969–977.

    Article  CAS  Google Scholar 

  14. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003; 101: 1715–1717.

    Article  CAS  Google Scholar 

  15. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002; 119: 665–671.

    Article  CAS  Google Scholar 

  16. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210–2216.

    PubMed  Google Scholar 

  17. Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM . MPC-1-CD49e− immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 1999; 105: 131–140.

    Article  CAS  Google Scholar 

  18. Bataille R, Robillard N, Pellat-Deceunynck C, Amiot M . A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev 2003; 194: 105–111.

    Article  CAS  Google Scholar 

  19. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR . Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999; 104: 131–137.

    Article  CAS  Google Scholar 

  20. Pope B, Brown R, Gibson J, Joshua D . The bone marrow plasma cell labeling index by flow cytometry. Cytometry 1999; 38: 286–292.

    Article  CAS  Google Scholar 

  21. Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 2004; 103: 3131–3137.

    Article  CAS  Google Scholar 

  22. Van Riet I, De Waele M, Remels L, Lacor P, Schots R, Van Camp B . Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol 1991; 79: 421–427.

    Article  CAS  Google Scholar 

  23. Jensen GS, Belch AR, Mant MJ, Ruether BA, Pilarski LM . Expression of multiple adhesion molecules on circulating monoclonal B cells in myeloma. Curr Top Microbiol Immunol 1992; 182: 187–193.

    CAS  PubMed  Google Scholar 

  24. Pellat-Deceunynck C, Barille S, Puthier D, Rapp MJ, Harousseau JL, Bataille R et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995; 55: 3647–3653.

    CAS  PubMed  Google Scholar 

  25. Ahsmann EJ, Lokhorst HM, Dekker AW, Bloem AC . Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 1992; 79: 2068–2075.

    CAS  PubMed  Google Scholar 

  26. Kawano MM, Huang N, Harada H, Harada Y, Sakai A, Tanaka H et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564–570.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by CA62242, CA107476, CA93842, CA100080, CA97274 and CN65125 from the National Cancer Institute, Bethesda, MD; and also supported in part by the Multiple Myeloma Research Foundation, the Goldman Philanthropic Partnerships and the Leukemia and Lymphoma Society.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    S Kumar, S V Rajkumar, T Kimlinger, P R Greipp & T E Witzig

Authors
  1. S Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Kimlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P R Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T E Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T E Witzig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S., Rajkumar, S., Kimlinger, T. et al. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 19, 1466–1470 (2005). https://doi.org/10.1038/sj.leu.2403823

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403823

Keywords

This article is cited by

Search

Advanced search

Quick links